We have examined the regulation of hepatic growth hormone receptors (GH-R) and serum GH binding proteins (GHBP) in transgenic mice expressing an antagonist of bovine growth hormone (bGH), G119K-bGH, and consequently exhibiting a growth suppressed dwarf phenotype. Specific GHBP could be measured in transgenic dwarf mouse serum only by immunological methods (RIA), because these mice have a very high concentration of mutated bGH in circulation (>1 µg/ml) and, therefore, almost all GHBP is bound to G119K-bGH and cannot be quantitated in binding assays. The concentrations of GHBP were 0·6 0·4 nM and 1·7 0·4 nM for normal and dwarf mice respectively. The concentrations of free GHBP in normal mice and in transgenic mice expressing wild-type GH can be calculated using chromatographic techniques as the dissociation constant (K d ) and the ratio of bound 125
I-GH to free 125 I-GH in the serum ([GHBP] free =B/F.K d ). In agreement with the assumption that GHBP reflects GH-R status, liver uptake of injected labeled bGH was greatly reduced in transgenic dwarfs in comparison with normal mice or with transgenic mice expressing wild-type bGH (liver/blood ratio of 0·48 0·21, 2·7 0·2, and 1·3 0·3 respectively) indicating that the high concentration of the mutated bGH (G119K-bGH) prevents labeled bGH uptake, as was expected from the dwarf phenotype.
125 I-bGH taken up by the liver of transgenic dwarf mice was found in a smaller molecular species than in normal mice, compatible with the presence of 1:1 [(GH-R):GH] complexes instead of the 2:1 [(GH-R) 2 :GH] or 2:2 [(GHBP) 2 :(GH) 2 ] complexes found in normal mice.
The concentration of IGF-I, the principal mediator of GH activity, in the G119K-bGH transgenic mice was correlated with the concentration of free GHBP. This allowed us to use free GHBP concentration as a marker of the effects of the active endogenous hormone (mGH) on liver receptors in the presence of different concentrations of the antagonist of GH.
The levels of GHBP in serum, as well as the concentration of GH-R in liver microsomes from mice expressing
Introduction
Bovine growth hormone (bGH) analogs produced by site-directed mutagenesis, G119R-bGH and G119K-bGH, competitively antagonize the action of endogenous GH both in vivo and in vitro (Chen et al. 1991a ,b, Chen et al. 1995 , Xu et al. 1995 . Since this inhibitory action and its physiological sequelae have not been completely characterized, we have examined the effects of this analog on the regulation and characteristics of hepatic GH receptor (GH-R) and serum GH binding protein (GHBP) , and on the concentration of insulin-like growth factor-I (IGF-I) in transgenic dwarf mice expressing G119K-bGH antagonist. Since overexpression of wildtype bGH in transgenic mice is associated with significant up-regulation of GH-R and GHBP (Aguilar et al. 1992 , Sotelo et al. 1995 , we were particularly interested in the effects of bGH antagonist on the levels of liver membrane GH-R and serum GHBP.
Since the levels of GHBP are closely related to GH-R levels (Amit et al. 1992 , Cramer et al. 1992b , Baumann et al. 1994a , Ilkbahar et al. 1995 , we have studied GHBP to obtain information on the competitive inhibition of GH binding by G119K-bGH in vivo. This was accomplished by estimating the concentration of free, unbound GHBP in normal mouse serum and in the presence of different concentrations of the antagonist. The concentration of free GHBP is an important parameter for monitoring the action of GH on the liver and for assessing the inhibitory effects of the antagonist on the actions of GH, such as stimulation of IGF-I levels. This information is pertinent to the evaluation of the potential usefulness of GH antagonists in the treatment of pathologies with supranormal levels of GH.
In this report, we also present evidence for the competitive inhibitory action of the G119K-bGH analog on the hepatic uptake of 125 I-bGH in vivo. Since the mechanism of GH action is thought to involve formation of 2:1 [(GH-R) 2 :GH] complexes on the membrane surface (Baumann et al. 1994b) and G119K bGH appears to form only 1:1 [(GH-R):GH] complexes as originally proposed by Chen et al. (1991a,b) , we discuss the implications of this finding for interpretation of the results obtained in transgenic mice overexpressing bGH antagonist.
Materials and Methods

Animals
Transgenic mice overexpressing the G119K-bGH gene linked to the promoter of mouse metallothionein-1 (MT) used in this work were derived from animals described previously (Chen et al. 1991a,b) . This line of transgenic mice was maintained by crossing transgenic mice with B6SJLF1/J nontransgenic individuals (Chen et al. 1991a ,b, Chen et al. 1995 . PEPCK-bGH transgenic mice were derived from males (kindly provided by Drs T E Wagner and J S Yun, Ohio University, Athens, OH, USA) carrying one (PEPCK-bGH-1) or five (PEPCK-bGH-5) copies of the wild-type bGH gene under the control of the regulatory sequences from the rat phosphoenolpyruvate carboxykinase gene. Transgenic animals from these lines differ in the level of bGH expression (Steger et al. 1994) .
Female mice were housed 3-5 per cage in a room with controlled light (12 h light/day) and temperature (22 2 C). The animals had free access to food (Lab Diet, Formulab 5008, containing a minimum of 23% protein, 6·5% fat, and a maximum of 4% fiber; PMI Feeds, Inc., St Louis, MO, USA) and tap water.
Hormones
Bovine GH was prepared in our laboratory (Turyn & Dellacha 1978) and human and mouse GH were obtained through the National Hormone and Pituitary Program, NIDDK, NIH, Bethesda, MD, USA.
Radioiodination of hormones
Human, bovine and mouse GH were radiolabeled using limiting amounts of Chloramine T, as previously described (Aguilar et al. 1992) . Specific activity ranged from 70 to 100 µCi/µg.
Radioreceptor and radioimmunoassays
Bovine (b) and mouse (m) GH levels were measured as described previously (Sotelo et al. 1993) . Mutated bovine growth hormone (G119K-bGH) was determined as bGH, using polyclonal antibodies against bGH as described by Chen et al. (1991a,b) . The radioreceptor assays (RRA) for mGH, bGH, and G119K-bGH were performed as previously described (Sotelo et al. 1995) .
Serum IGF-I concentrations were measured, after extraction of its binding proteins, by RIA using a commercial kit for rat IGF-I from Diagnostic Systems Laboratories, Webster, TX, USA.
In vivo 125 I-bGH uptake
Determinations of the specific liver uptake and the molecular weight (MW) of radioactive complexes present in the liver were performed as previously described (Turyn & Bartke 1993 , Turyn et al. 1997 .
Microsomes binding assay
The 125 I-bGH binding assay was carried out as previously described (Aguilar et al. 1992 ) using liver microsomes obtained according to Borst & Sayare (1982) , with an additional washing step using 50 mM ethanolic acid buffer (pH 5·0) to remove bound GH. Four to six livers were pooled for each membrane preparation.
GHBP assays
Chromatographic assays for GHBP were performed as previously described (Sotelo et al. 1995) . The RIA for GHBP was performed as described (Cramer et al. 1992a) except that the 28 amino acid synthetic peptide of mouse GHBP C-terminus coupled to keyhole limpet hemocyanin (KLH), used in order to obtain antibodies against the GHBP, was from TANA Laboratories, Houston, TX, USA. This peptide was also used for the standard curve (Smith et al. 1989 , Cramer et al. 1992b , Sotelo et al. 1995 .
Processing data
The amounts of bound and free GHBP were calculated as B/F ratio concentration of free GH (determined by RRA), and B/F ratio K d , where K d , B and F represent the dissociation constant, bound and free hormone concentrations respectively (Hochberg et al. 1993 , Sotelo et al. 1995 . Total GHBP was calculated by summation of bound and free GHBP values. The non-linear regression curve-fitting program Ligand (Munson & Rodbard 1980) was used to analyze competition studies. The Scatchard analyses (Scatchard 1949) of competitive curves were used to derive estimates of the apparent dissociation constants (K d ) and binding site capacities (B max ). Data are presented as means ...; statistical differences between groups were determined using Student's paired or unpaired t-tests. When multiple comparisons were performed, the data were analyzed by ANOVA.
Chemicals
Ovine prolactin (oPRL) was from Sigma Chemical Co. (St Louis, MO, USA); keyhole limpet hemocyanin (KLH) was from Calbiochem Behring (La Jolla, CA, USA) and Na 125 I was purchased from Dupont (Boston, MA, USA). All other chemicals were of reagent grade.
Results
Data on body weights, concentrations of GH measured by both RIA and RRA, and concentrations of IGF-I for the animals used in the present study are given in Table 1 . It is important to emphasize that RRA measures available GH while RIA measures total GH concentration (Hochberg et al. 1993) . The ratio of GH concentration measured by RRA to that measured by RIA ranged between 0·6 and 0·9 (Table 1) . Serum binding of 125 IbGH and/or 125 I-hGH was analyzed on 1·5 11·0 cm Sephacryl S200 HR columns, in order to obtain quantitative results and minimize dissociation of GH-GHBPs complexes during chromatography (which was less than 8% after 20 min, the mean retention time of the GH-[GHBP] complexes). Two peaks of radioactivity were detected as expected from our previous studies (Sotelo et al. 1995) . The first peak accounts for 125 I-GH bound to GHBPs, and the second peak represents free 125 I-GH (Fig. 1A) . Figure 1 shows representative elution profiles of 125 I-hGH incubated alone or together with an excess of unlabeled hGH with serum from normal or transgenic mice. Matched comparisons between normal, transgenic PEPCK-bGH-1, transgenic PEPCK-bGH-5 and transgenic dwarf mice serum samples revealed major differences in binding of 125 I-GH to serum GHBP, expressed as a percentage (%) of total 125 I-GH added (Table 2 ). For G119K-bGH transgenic dwarf mice, labeled GH specifically bound to serum binding protein(s) did not differ from the values of non-specific binding in almost all of the samples measured ( Table 2) .
The dissociation constant of bGH binding to normal mouse serum calculated by Scatchard analysis of data was 6·3 1·7 nM (n=3). The concentrations of GHBP determined by the chromatographic method and by the specific RIA for mouse GHBP are shown in Table 3 . Table 2 also includes the values of specific 125 I-bGH binding to liver microsomes obtained from normal and transgenic mice used in this study. Labeled bGH was used in order to determine somatogenic binding sites because bGH cannot be bound by the mouse prolactin receptor (Amit et al. 1992) . In G119K-bGH transgenic mice, GH binding to the liver microsomes was increased by 85% over the values obtained for normal (non-transgenic) mice, while a 220-275% increase was obtained in microsomes from livers of transgenic mice overexpressing wild-type bGH (Table 2) . Table 4 shows the in vivo liver uptake measured 30 min after injecting 125 I-bGH either alone or together with an excess of unlabeled bGH, in normal and transgenic mice. The radioactivity taken up by the liver of normal mice and transgenic dwarf mice expressing G119K-bGH was analyzed on a Sepharose CL-6B column and is shown in Fig. 2 .
In transgenic dwarf mouse plasma, the concentration of IGF-I corresponds to 36·7 7·4% of the values measured in normal mice, while in transgenic PEPCK-bGH-1 mice expressing high concentrations of native bGH, plasma concentrations of IGF-I were increased 121 18·5% over non-transgenics (Table 1) . 
Discussion
Numerous findings support the idea that circulating GHBP levels reflect GH-R status (Baumann et al. 1994a) . However, the regulation of GHBP and/or GH-R is not fully elucidated, and some controversial findings were reported in former animal studies (Turyn & Dellacha 1978 , Amit et al. 1992 . We have demonstrated upregulation of GH-R in liver membranes and GHBP in serum in transgenic mice expressing different levels Table 2 . of heterologous GH (Aguilar et al. 1992 , Sotelo et al. 1995 .
In the present work we have examined the levels of GHBP in transgenic mice expressing a bGH analog (G119K-bGH) that antagonizes the action of wild-type GH, and compared the results with those obtained in normal mice and two lines of transgenic mice expressing different amounts of wild-type bGH (Sotelo et al. 1995) .
We have used chromatographic and immunological techniques to measure free and total GHBP respectively (Hochberg et al. 1993 , Sotelo et al. 1995 , since we have previously found a good correlation between free GHBP measurements using this technique and results of a specific GHBP RIA for normal and transgenic mice overexpressing wild-type GH (Sotelo et al. 1995) . In normal mice, an important fraction of GHBP was bound to GH, in agreement with previous observations (Sotelo et al. 1995) . In PEPCK-bGH-5 and PEPCK-bGH-1 mice, the percentage of free GHBP was reduced in direct proportion to available GH plasma levels as determined by RRA (Hochberg et al. 1993) . In transgenic G119K-bGH dwarf mice, all detectable GHBP is bound to the GH antagonist in agreement with the observation that no significant binding of 125 I-GH was detected ( Fig. 1D and Table 2 ). Previously, we had observed an increase in GHBP levels in transgenic mice expressing the wild-type bGH gene, in which plasma GH levels were elevated up to 40-fold, compared with non-transgenic mice (Sotelo et al. 1995) . These animals provide excellent models to estimate the increase and saturation of GH-R and GHBP due to the elevated concentration of available GH, and to compare them with the results obtained for the mice expressing the bGH antagonist. This allows us to I-bGH taken up in vivo by the liver of non-transgenic (normal) mice (A) and G119K-bGH transgenic (B) mice. The livers from female mice that had previously been injected i.v. with 125 I-bGH alone () or with 300 g/50 g body weight unlabeled bGH () were homogenized in Tris-HCl buffer (25 mM), pH 7·4, containing 1% Triton X-100, and centrifuged at 100 000 g for one hour. An aliquot of the supernatant (0·8-1·5 ml) was chromatographed on a Sepharose CL-6B column (see Materials and Methods). The arrows indicate the elution volume of Blue Dextran (V 0 ), distinguish between the effects of GH agonists and antagonists in mice. As is shown in Table 3 , the levels of GHBP were increased only 180% over control values in transgenic dwarf mice overexpressing G119K-bGH, while an increase of 550-650% over control was found in both lines of transgenic mice expressing different amounts of the wildtype bGH. This is in spite of the G119K-bGH concentration being between 2 and 9 times higher in the transgenic dwarf mice than the bGH levels in the other transgenic lines (Table 1) . A similar conclusion could be made from the values of 125 I-bGH bound to liver microsomes from normal and transgenic mice ( Table 2 ). The up-regulation of both GHBP and GH-R by the bGH antagonist, although smaller in magnitude than that in transgenic mice overexpressing wild-type bGH, suggests that G119K-bGH is internalized in order to induce the synthesis of the receptor and the binding proteins, as was proposed by Harding et al. (1996) and Chen et al. (1991a,b) . Since no binding of 125 I-GH was found in the serum of transgenic dwarf mice, almost all of the GHBP is bound to mutated G119K-bGH ( Fig. 1 and Table 2 ), clearly demonstrating that the GH antagonist could saturate the GHBP in vivo. Considering that the affinity constants for GH-R and GHBP are comparable (Hochberg et al. 1993) , GH receptors should also be saturated in these mice. This conclusion is further supported by the fact that the uptake of labeled bGH in these transgenic mice is essentially reduced to values of nonspecific uptake (Table 4; Turyn & Dellacha 1978 , Turyn & Bartke 1993 , Turyn et al. 1997 . From these results, it is possible to calculate the concentration of GH antagonist needed to reduce the amount of endogenous mGH bound to the receptor and consequently to reduce its biological activity. A concentration over 2000 ng/ml is necessary to prevent completely the binding of active GH (data not shown). These data represent a mean competition constant (ED 50% ) of 8 and 10·6 nM (180 and 240 ng/ml) for bovine and human GH respectively, consistent with a K d of 6·3 nM obtained for normal mice. The value of K d for normal mice is in agreement with previous data for normal and transgenic mice, including transgenic dwarf mice (Chen et al. 1991a ,b, Baumann et al. 1994a , Chen et al. 1995 , Sotelo et al. 1995 . We calculated the ED 50% values, since the concentration of total GHBP as well as that of GH-R are different in the four types of mice studied (Table 3) . Lower concentrations of GH antagonist allow more of the available mGH to bind, and thus to exhibit biological activity. Consequently, an extremely high concentration of the antagonist (up to 2000 ng/ml) should be considered for potential use in medical therapy. The result represents a balance between the up-regulation of membrane GH-R, that produces an increase in GH-dependent activities, and the inhibition of mGH binding, that leads to suppression of GH-dependent activities. One of the principal actions of GH is to stimulate IGF-I production, primarily in the liver, following active GH binding to its receptor(s) (Zapf & Froesch 1986) . For this reason, the determination of IGF-I concentration should correspond to the inhibition of mGH binding to liver receptors in the presence of the GH antagonist.
It is interesting to note that some transgenic dwarf mice express GH concentrations which are much lower than the average (2013 ng/ml), as was previously reported (Chen et al. 1991a ,b, Chen et al. 1995 . These smaller concentrations of GH antagonist generally produce lesser or no reduction of body weight (Chen et al. 1991a ,b, Chen et al. 1995 . This was seen in 3 individuals among the 27 transgenic dwarf mice used in the present study. In these three mice, the concentrations of bGH antagonist were 399, 590 and 850 ng/ml, and the percentage of 125 I-hGH bound to serum GHBP was substantially higher (15·3%, 14·8%, and 7·0% respectively) than the values obtained in the remaining 23 transgenic dwarf mice: 0·8 1·1% for 125 I-bGH and 1·1 1·0% for 125 I-hGH (Table 2) . These values are in agreement with a linear relationship found for the percentage of 125 I-hGH bound to serum from normal mice and transgenic mice expressing wild-type bGH or G119K-bGH and the log of GH concentration. This agreement can be extended to IGF-I levels, since maximal inhibition of IGF-I production was seen in G119K-bGH mice expressing high concentrations of the analog, while a less severe inhibition of IGF-I production was seen in three transgenic dwarf mice with low plasma levels of G119K-bGH (data not shown). These observations provide the basis for using the concentration of free GHBP as a tool to assess the B/F ratio of liver GH-R and to relate it to its activity.
The MW of the GH:(GH-R) complexes obtained for normal mice is in accordance with previous data for normal and transgenic mice overexpressing wild-type GH, and is compatible with the structure of 1:2 [GH:(GH-R) 2 ] or 2:2 [GH 2 :(GH-R) 2 ] complexes, with a Stokes radius of 64 A (Ciccia-Torres et al. 1983 , Turyn & Bartke 1993 , Harding et al. 1996 , Turyn et al. 1997 . The complexes obtained in vivo for transgenic mice overexpressing the bGH antagonist had a significantly smaller MW (peak III in Fig. 2B ) than those obtained for normal mice (peak II of Fig. 2A) , suggesting that the antagonist is unable to generate the dimerization of the GH-R, as was previously reported (Chen et al. 1991a ,b, Chen et al. 1995 , Harding et al. 1996 . The GH-R bound to 125 I-bGH is unable to dimerize, since almost all of the receptors are bound to the G119K-bGH analog, and no free, accessible GH-R molecules are available ( Fig. 2 and Tables 2 and 3) .
In summary, we have demonstrated the presence of GHBP in the plasma of transgenic G119K-bGH dwarf mice and provided evidence that the concentration of bGH analog in the circulation of most of these animals is sufficient to completely saturate circulating GHBP and GH-R in vivo. In transgenic mice expressing the bGH antagonist G119K-bGH, the concentration of IGF-I, the principal mediator of GH activity, could be correlated to the percentage of 125 I-GH bound to serum. Since the labeled hormone can only bind to free GHBP, we believe that the concentration of free GHBP could be applied as a simple method to evaluate the potential utility of the use of GH antagonists in clinical therapy. G119K-bGH was suggested to be internalized in transgenic dwarf mice as 1:1 (GH:[GH-R]) complexes. Further work will be necessary to elucidate the mechanism(s) responsible for the ability of the G119K-bGH analog devoid of somatogenic activity to up-regulate the levels of the GH-R and GHBP (Chen et al. 1991a,b) .
